Supply sovereignty in Europe

How we reduce supply shortages

Global supply chain disruptions and an increasing dependency on low-cost regions repeatedly lead to shortages in the supply of pharmaceutical products. Complex Pharmaceuticals faces this challenge with a regional high-end packaging facility which processes both clinical trial material and commercial micro-, small- and large batches. Our aim is to ensure supply sovereignty in Europe and provide reliable access to pharmaceutical products.

FAQ

Causes of shortages

  • Global dependency: Since a major part of the materials is produced in low-cost regions, even minor disruptions such as transport bottlenecks, can have noticeable effects on Europe; In the case of a major crisis like a pandemic, these impacts are significantly amplified.
  • Regulatory pressure: Strict requirements increase the complexity of supply chains.
  • Rising demand: Increasing requirements and new therapies are steadily driving up the need for pharmaceutical products.
  • Crises & Natural disasters: Pandemics, trade conflicts and geopolitical tensions have a direct and immediate effect on transportation.

Our solution

Regional high-end packaging

Complex Pharmaceuticals is investing in a modular high-end production facility near Vienna. The plant processes small and large batches under the highest quality standards, individually packages clinical trial materials, and allows rapid format changes (vials, ampoules, blisters). In this way we are able to respond rapidly to market demands and shorten lead times.

Advantages of regional production

  • Shorter supply routes: Nationally produced medicines reach patients more quickly.
  • Qualified professionals: Austria offers excellent infrastructure and highly skilled experts.
  • Regulatory stability: Highest quality standards.
  • Resilient supply: National capacities ensure supply even in crisis situations.

Ensuring supply, reducing dependencies – together with Complex Pharmaceuticals.

Schedule a non-binding consultation with us to create a tailor-made strategy for a resilient, future-proof pharmaceutical supply – from short-term project solutions to long-term location strategies.

contact

Questions and answers

Dependencies, resilience, supply sovereignty and local production

A major reason lies in the high level of dependence on international active ingredient and production sites. Since a significant share of the materials is produced in low-cost regions, even minor disruptions such as transport bottlenecks can have noticeable effects on Europe; in the case of a major crisis like a pandemic, these impacts are significantly amplified. The targeted expansion of production and packaging capacities within Europe reduces this dependency and sustainably strengthens security of supply.

Supply sovereignty describes the ability of a country or economic area to produce and package critical pharmaceutical products in sufficient quantities domestically. The aim is to ensure a reliable supply for patients – independent of global shortages or external crises.

A packaging facility that is aligned with market and patient demand shortens transport routes, enables short-term format and batch changes, and ensures availability – especially in sensitive areas such as clinical trials or the supply of specialty medicines.

Austria offers a central location in the European healthcare landscape, excellent connectivity to international transport routes, a pharma-friendly regulatory environment and access to highly skilled professionals. This combination creates ideal conditions for a stable and competitive supply of pharmaceutical products.

Email

office@complex-pharma.com

OFFICE

Complex Pharmaceuticals GmbH
Storchengasse 1
1150 vienna | Austria

PHONE

Office hours
Mo to Fr. 09:00 to 18:00 o’clock
Tel: +43 1 208 01 34